ArticleBMC pulmonary medicine2025

Clinical outcomes after switching from omalizumab to anti-IL-5/IL-5R biologics in severe asthma: a retrospective cohort study.

Fatma Arzu Akkuş et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.